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Gregory L. Moneta, MD, Section EditorBotox Therapy for Ischemic Digits
Neumeister MW, Chambers CB, Herron MS, et al. Plast Reconstr Surg
2009;124:191-200.
Conclusion: Botox appears to provide improvement in digital perfu-
sion and pain reduction in patients with Raynaud’s syndrome when conser-
vative management fails.
Summary: Digital ulceration associated with Raynaud’s syndrome is
painful, difficult to treat, and frequently results in patient debilitation and
chronic depression. Reports by Sycha and Van Beek have indicated potential
benefit for patients with ischemic digits with local injection of botulinum
toxin (Euro J Clin Invest 2004;34:312-3; Plast Reconstr Surg 2007;119:
217-26). This was a retrospective observational study on outcomes of 19
patients with Raynaud’s syndrome treated with botulinum toxin. All patients
had chronic ischemic hand pain, and vascular studies had ruled out proximal
occlusive disease and underlying disorders, including carpal tunnel syn-
drome, diabetes, renal failure, rheumatoid arthritis, hypothenar hammer
syndrome, scleroderma and mixed connective tissue disease as well as lupus.
Thirteen patients had chronic finger ulcers. Botox (50 to 100 U) was
injected into the palm around each involved neurovascular bundle. Prein-
jection and postinjection laser Doppler studies were performed in most
patients to assess potential changes in digital blood flow.
Of the 19 patients treated, 16 (84%) reported reduction of pain, 13
reported immediate pain relief, 3 more had gradual pain relief over 1 to 2
months, and 3 patients had no or minimal response. Laser Doppler studies
demonstrated markedly increased blood flow to the treated digits. The
chronic finger ulcers in the 13 patients healed 60 days. Twelve patients
(63%) remained pain free with a single injection at 13 to 59 months after
injection. Four patients (21%) required additional injections because of
recurrent pain.
Comment: In addition to its cosmetic uses, Botox is receiving in-
creased attention for treatment of widely varying disorders, from anal fissures
to ischemic digital ulcers. Its mechanism of action is unclear, although some
speculate that it may work through modulation of vascular tone or blockage
of chronic neuropathic pain pathways. This study was not controlled, and it
is well known that patients with finger ulcers often have a waxing and waning
course and that many ulcers will heal with conservative therapy. However, if
the results of Botox therapy for ischemic ulceration of the fingers are as truly
dramatic as depicted in this report, it should not be difficult to design a
blinded trial with sufficient power to definitely prove the efficacy of this
treatment.
Dabigatran Versus Warfarin in the Treatment of Acute Venous
Thromboembolism
Schulman S, Kearon C, Kakkar AK, et al; the RE-COVER Study Group.
N Engl J Med 2009;361:2432-52.
Conclusion:A fixed dose of dabigatran, an oral anticoagulant that does
not require monitoring, is as effective as warfarin in the treatment of acute
venous thromboembolism (VTE) and has a similar safety profile.
Summary: Dabigatran is an orally available, potent, direct inhibitor of
thrombin that is administered in a fixed dose, with no need for coagulation
monitoring. Its half-life is 12 to 17 hours, and it is excreted in the urine.
Dabigatran has demonstrated similar safety and efficacy as an enoxaparin in
prevention of VTE in patients undergoing hip or knee arthroplasty (J
Thromb Haemost 2007;52178-85; Lancet 2007;370:949-56). It has also
has similar safety and, in some cases, superior efficacy in the prevention of
stroke in patients with atrial fibrillation (N Engl J Med 2009;361:1139-51).
This was a double-blind, randomized, noninferiority trial comparing
dabigatran with warfarin for treatment of acute VTE. Patients with acute
VTE were initially given parenteral anticoagulation therapy for a median of
9 days (interquartile range, 8-11 days). Patients randomized to dabigatran
received 150 mg twice daily. Patients randomized to warfarin were treated
with dose adjustment to achieve an international normalized ratio (INR) of
2.0 to 3.0. The primary outcome was recurrent, symptomatic, objectively
confirmed VTE and related deaths at 6 months. Safety end points included
bleeding, acute coronary syndromes, liver function tests, and other adverse
events.
Dabigatran was given to 1274 patients, and 30 (2.4%) had a recurrent
thromboembolic event. Warfarin was given to 1265 patients, and 27 (2.1%)
had recurrent VTE. The difference in risk was 0.4% points (95% confidence
interval [CI], –0.8 to 1.5; P  .001) for the prespecified not inferiority
margin. The hazard ratio for dabigatran was 1.10 (95% CI, 0.65-1.84).
Major bleeding occurred in 20 patients (1.6%) assigned to dabigatran and in
24 (1.9%) treated with warfarin. The hazard ratio with dabigatran was 0.82
(95% CI, 0.45-1.48). Any bleeding was observed in 205 patients assigned to
522dabigatran (16.1%) and in 277 patients assigned to warfarin (21.9%), and the
hazard ratio with dabigatran was 0.71 (95% CI, 0.59-0.85). The two groups
had similar numbers of deaths, acute coronary syndromes, and abnormal
liver function test results. The drug was discontinued due to adverse events
in 9% of patients assigned to dabigatran and in 6.8% of patients assigned to
warfarin (P  .05).
Comment: The data indicate dabigatran is not inferior to warfarin
when used to treat patients with acute VTE when warfarin is adjusted to
maintain an INR of 2.0 to 3.0. The only previously available oral, direct
thrombin inhibitor was ximelagatran. This was also not inferior to warfarin
for treatment of recurrent VTE, but there were infrequent but serious
hepatic toxic effects thus far not seen with dabigatran. Dabigatran is cleared
in the urine, and90% of the patients in this study had a creatinine clearance
of 50 mL/min. Obviously, additional patients with varying levels of renal
dysfunction will need to be studied. Accumulating evidence supports dabig-
atran as a fixed-dose alternative to warfarin. The drug has no known
interactions with foods and minimal reactions with other drugs. The days of
using rat poison to treat VTE may be drawing to a close.
Heparin Induced Thrombocytopenia and Thrombosis in a Tertiary
Care Hospital
Ban-Hoefen M, Francis C. Thromb Res 2009;124:189-92.
Conclusion: The occurrence of heparin-induced thrombocytopenia
(HIT) can be decreased by reducing the exposure to unfractionated heparin.
The diagnosis can be improved by reporting the optical density of the
enzyme-linked immunosorbent assay (ELISA) test result.
Summary: HIT results from the development of an antibody reacting
with a complex of heparin and platelet factor 4 that results in thrombocyto-
penia and a hypercoagulable state. Clinical diagnosis depends on a combi-
nation of a decline in platelet count, the duration of platelet therapy, and the
occurrence of thrombotic events. The most widely used diagnostic test for
HIT is an ELISA that detects the presence of antibodies reactive with the
heparin platelet factor 4 complex. The tests are very sensitive but lack
specificity. A negative test is useful for excluding the diagnosis.
The authors sought to determine the frequency, clinical characteristics,
and laboratory correlates of HIT in a tertiary care hospital. They undertook
a retrospective record review of all adults hospitalized during a 30-month
period. Patients who had a positive antiplatelet factor 4 ELISA assay were
identified through an institutional laboratory database. Data were analyzed
for the type, dosage, and route of administration of heparin associated with
HIT.
HIT was diagnosed in 136 patients, including 114 of 28,091 patients
(0.48%) who received only unfractionated heparin. It was diagnosed in
22 of 6559 patients (0.33%) who received both unfractionated and
low-molecular-weight (LMW) heparin. HIT was diagnosed in 2 of 2498
patients (0.8%) who received only LMW heparin (P  .02 compared with
those who received only unfractionated heparin). HIT occurred in 62 of
16,939 patients receiving subcutaneous heparin or LMW heparin compared
with 69 of 11,152 patients receiving intravenous therapy (P .003). Of the
34,650 patients exposed to heparin products, symptomatic thrombosis
developed in 41 (0.1%). The optical density of the ELISA assay was 1.2 
0.8 in patients with HIT and thrombosis and 0.9  0.6 in those without
thrombosis (P  .03).
Comment: The data in this study indicate HIT develops in about 0.4%
of all patients exposed to heparin in a tertiary care hospital and is significantly
less frequent in those treated only with LMW heparin. These authors’
findings are consistent with previous reports. A new bit of information is the
association of the optical density value of the ELISA assay with thrombotic
complications of HIT. The Food and Drug Administration requires ELISA
assays for HIT to be reported as positive or negative based on a certain
threshold value. The data suggest that reporting of the actual optical density
may be useful in determining which patients with HIT are at most risk for a
thrombotic complication.
Prediction of Hypertension Improvement After Stenting of Renal
Artery Stenosis: Comparative Accuracy of Translesional Pressure Gra-
dients, Intravascular Ultrasound, and Angiography
Leesar MA, Varma J, Shapira A, et al. J Am Coll Cardiol 2009;53:2363-71.
Conclusion: A hyperemic systolic pressure gradient 21 mm Hg
predicts improvement in hypertension after stenting of renal artery stenosis.
Summary: Correlation is poor between the percentage of renal artery
stenosis measured by renal angiography and translesional pressure gradients
across the renal artery stenosis. It is postulated therefore that the discordance
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may, at least in part, stem from the limitations of angiography and the assess-
ment of the significance of renal artery stenosis. The authors therefore sought to
compare the diagnostic accuracy of renal artery translesional pressure gradients,
intravascular ultrasound (IVUS) imaging, and angiographic parameters in pre-
dicting hypertension improvement after stenting of renal artery stenosis. Their
hope was to establish criteria where stenting of the renal artery can be justified by
improved hypertension control.
Sixty-two patients with renal artery stenosis had assessment of trans-
stenosis pressure gradients (resting and hyperemic systolic gradient, frac-
tional flow reserve, and mean gradients) as measured by pressure guidewires
and IVUS and angiographic parameters of minimal lumen diameter such as
area stenosis and diameter stenosis. Patients with renal artery stenosis were
enrolled in the study if the systolic blood pressure was140 mm Hg or the
diastolic blood pressure was 90 mm Hg, or both, or they had accelerated
or refractory hypertension on two or three antihypertensive medications.
Hypertension improvement was defined as a diastolic blood pressure of90
mm Hg or a systolic blood pressure of140 mm Hg, or both, or a reduction
in diastolic blood pressure by at least 15 mm Hg with the same or reduced
number of antihypertensive medications. Receiver-operating characteristic
(ROC) analysis determined optimal cutoff values of transpressure gradients,
IVUS parameters, and angiographic parameters in predicting hypertension
improvement at 12 months. Cut points that yield the greatest sum of
sensitivity and specificity were selected. The area under the curve for the
ROC (AUROC) analysis was compared for each of the hemodynamic and
anatomic parameters assessed.
Hyperemic pressure gradients were determined across the renal artery
stenosis by first advancing the pressure wire through the stenosis and then
injecting a 30-mg bolus of papaverine into the renal artery. After the
papaverine injection, the guiding catheter was retracted from the ostial of the
renal artery and the renal artery pressure gradients were obtained.
The hyperemic systolic pressure gradient had a larger AUROC curve
than most other parameters. A hyperemic systolic pressure gradient21 mm
Hg had the highest sensitivity, specificity, and accuracy (82%, 84%, and 84%)
in predicting hypertension improvement after stenting of renal artery steno-
sis. Stenosis as determined by the average IVUS area was significantly greater
in renal artery lesions with a hyperemic systolic pressure gradient 21 mm
Hg vs those with gradients 21 mm Hg (78% vs 38%, P  .001). In 36
patients with hyperemic systolic pressure gradients 21 mm Hg, hyperten-
sion improved in 84% after renal artery stenting. In patients with hyperemic
systolic gradients21 mm Hg, hypertension improved in 12 months in 36%
of patients (n  26, P  .01). Multivariable analysis showed the hyperemic
systolic pressure gradient was the only parameter that independently pre-
dicted hypertension improvement (odds ratio, 1.39; 95% confidence inter-
val, 1.05-1.65; P  .013).
Comment: The problem with this study, of course, is that hyperemic
systolic pressure gradients can only be obtained once a catheter is placed
across the renal artery lesion. The practical point is that once someone has
placed a wire across the renal artery lesion, it would be very difficult to avoid
the temptation to stent that lesion regardless of the pressure gradient
measured. The concept that hemodynamic gradients are more important
than the angiographic severity is likely valid and makes sense. A correlation
with hyperemic systolic pressure gradients with ultrasound findings would
seem to be the next step in trying to determine the practicality of hyperemic
pressure gradients in selecting patients for renal artery stenting. See also the
abstract “Revascularization vs. medical therapy for renal-artery stenosis” by
the ASTRAL investigators in this abstract section of the journal.
Racial and Ethnic Disparities in Outcomes and Appropriateness of
Carotid Endarterectomy: Impact of Patient and Provider Factors
Halm EA, Tuhrim S, Wang JJ, et al. Stroke 2009;40:2493-501.
Conclusion: Minorities have worse outcomes and higher rates of
inappropriate carotid endarterectomy (CEA).
Summary: There are many variables that lead to inequities in quality
and outcomes of health care. Access to care, particularly adequate insurance,
appears to be a major driver of disparities in care. However, inequities exist
even among well-insured patients. Other possible drivers of inequities in
health care include racial and ethnic differences and underlying social
demographic characteristics, as well as severity of comorbid illnesses and
overall disease burden. Minority patients may also receive care by physicians
and in hospitals with lower levels of cultural competence than would be
ideal. There is therefore a current emphasis on identifying how patients’
disease burden and physician or hospital factors, or both, can contribute to
disparities among care in minority patients.
This study evaluated disparities and outcomes of CEA with respect to
race and ethnicity. This was a population-based cohort of CEA patients
derived from a list of Medicare beneficiaries in New York. Data were
abstracted from medical records to assess social demographics, disease
severity, comorbidities, indication for CEA, and strokes and deaths within
10 days of surgery. Appropriateness of CEA was based on validating criteria
from a national expert panel. Differences in providers, patients, appropriate-
ness of surgery, and outcomes were compared using 2 tests. Multiplelogistic regression analysis was used to evaluate differences in risk-adjusted
rates of death or nonfatal stroke with adjustments for patient, physician, and
hospital-level risk factors.
Of 9093 patients undergoing CEA overall, 95.3% were white, 2.5%
were black, and 2.2% were Hispanic. Analysis indicated minorities had more
severe neurologic disease, more comorbidity, and were more likely to be
cared for by lower-volume surgeons and hospitals (P  .0001). The 30-day
stroke and death rates were higher in Hispanics (9.5%) and blacks (6.9%)
than in whites (3.8%, P .0001). When adjusting for presurgical patient risk
and provider characteristics, multivariable analysis indicated that blacks no
longer had significantly worse outcomes (odds ratio, 1.37; 95% confidence
interval, 0.78-2.40). Even after adjustments, however, a higher risk of death
and stroke persisted in Hispanic patients (odds ratio, 1.87; 95% confidence
interval, 1.07-3.19). This was largely due to higher comorbidity in minori-
ties and higher rates of inappropriate surgery (Hispanics, 17.6%; blacks,
13.0%; whites, 7.9%; P  .0001).
Comment: This study suggests that, at least with regard to endarter-
ectomy, surgical outcomes in minority patients are driven largely by patient
presurgical risk and experience and skill of the specific physicians performing
the procedure. That Hispanic patients have the highest incidence of periop-
erative stroke after CEA is a new finding. Adjustment for patient, surgeon,
and hospital factors diminished excess risk among Hispanics, but Hispanic
patients still had nearly double the risk of death or stroke in the multivariable
model used. The interaction of Hispanic people with the medical system has
received relatively little attention. Thankfully, this now appears to be chang-
ing.
Revascularization vs Medical Therapy for Renal-Artery Stenosis
The ASTRAL Investigators. N Engl J Med 2009;361:1953-62.
Conclusion: There is no significant clinical benefit from renal artery
revascularization in patients with renal artery atherosclerotic disease.
Summary: Renal artery stenosis is associated with chronic kidney
disease and hypertension. It is, however, not clear that these associations are
causal. In fact, three small randomized control trials have showed no benefit
of renal artery angioplasty compared with medical therapy (Hypertension
1998;31:823-9; J Hum Hypertens 1998;12:329-35; N Engl J Med 2000;
342:1007-14). These studies were small and underpowered to detect po-
tentially clinically worthwhile improvements in renal function, blood pres-
sure, or mortality rates. The current Angioplasty and Stent for Renal Artery
Lesions (ASTRAL) trial is a randomized unblinded trial in which 806
patients with atherosclerotic renal vascular disease were assigned to undergo
medical therapy alone or renal revascularization (renal angioplasty with or
without a stent and without renal protection) in addition to medical therapy.
Renal function measured by the reciprocal of the serum creatinine level (a value
that has a linear relationship with creatinine clearance) was the primary outcome
measure. Secondary outcomes were the times to renal and major cardiovascular
events, death, and blood pressure. Medium follow-up was 34 months.
During a 5-year period, progression of renal impairment (defined by
the slope of the reciprocal of the serum creatinine level) was –0.07  10–3
L/mol per year in the revascularization group and –0.13 10–3 L/mol
per year in the medical therapy group. This difference of 0.06  10–3
L/mol per year favors revascularization (95% confidence interval [CI],
–0.002 to 0.13; P .06). Mean serum creatinine was 0.02 mg/dL lower in
the revascularization group than in the medical therapy group (95% CI,
–0.10 to 0.06). There was no significant difference between groups in
systolic blood pressure. The decrease in diastolic blood pressure was smaller
in the revascularization group than in the medical therapy group. There were
similar rates of renal events in the two groups (hazard ratio in the revascu-
larization group: 0.97; 95% CI, 0.67-1.4; P  .88). There were no signifi-
cant differences in major cardiovascular events (P .61) and death (P .46)
between the two groups. In the revascularization group, 23% of patients had
significant complications associated with revascularization, including three
amputations of toes or limbs and two deaths.
Comment: The study indicates no benefit from revascularization in
patients with renal artery stenosis. The authors also performed post hoc
analyses in smaller subpopulations of patients. They found no evidence of
benefit of revascularization in patients with bilateral renal artery stenosis
70% or renal artery stenosis 70% in a single functioning kidney. There
was also no significant difference in outcome between patients with severe
renal artery stenosis vs those without severe disease. Renal artery revascular-
ization for atherosclerotic disease should now be a rare event. Treatment of
renal artery stenosis simply because “it can’t be a good thing” cannot be
justified.
Secondary Intervention After Endovascular Abdominal Aortic Aneu-
rysm Repair
Conrad MF, Adams AB, Guest JM, et al. Ann Surg 2009;250:383-9.
Conclusion: Secondary interventions are common after endovascular
aneurysm repair but do not adversely affect aneurysm related death or overall
actuarial 5-year survival.
